| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA933: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) |
|
Medicine details |
|
| Medicine name | tisagenlecleucel (Kymriah®) |
| Formulation | dispersion for infusion |
| Reference number | 3931 |
| Indication | Treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma after two or more lines of systemic therapy |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/08/2018 |
| NICE guidance | |